SCHERING-PLOUGH EMPLOYEES' SAVINGS PLANS

On January 14, 2008, Schering-Plough Corporation, ("Schering-Plough" or the "Company") (NYSE: SGP) revealed severe safety and efficacy issues related to its leading cholesterol drug Vytorin and that Schering-Plough had delayed the publication of a study, that they possessed allegedly demonstrating that Vytorin was not as safe or effective as previously represented Schering-Plough and other administrators of the Schering-Plough Employees' Savings Plans (the "Plans") may have breached their ERISA-mandated fiduciary duties of loyalty and prudence to participants and beneficiaries of the Plans. A breach may have occurred if the fiduciaries failed to manage the assets of the Plans prudently and loyally by investing the assets in Company stock when it was no longer a prudent investment for participants' retirement savings.

Schering-Plough employees who own Schering-Plough stock through the Plans may be able to recover some of their losses. If you or anyone you know is a member of the Schering-Plough Plans and purchased Schering-Plough stock through the Plans, please complete a Schering-Plough Complaint Form for a free evaluation.

Schering-Plough Employee Savings Articles

Schering-Plough: Dragging Heels on Vytorin Study, a Breach of ERISA?
The long-awaited, and long-delayed release of the ENHANCE study on the effects and efficacy of the cholesterol drug Vytorin (Zocor combined with Zetia) may have done more than raise the ire of doctors and the medical community: it also may have ticked off investors of Schering-Plough, one of the two manufacturers involved in Vytorin. The delay may translate into a breach of ERISA-mandated fiduciary duty regarding employees participating in a Schering-Plough pension plan.

Schering-Plough Employee Savings Plan Legal Help

If you or a loved one has suffered damages in this case, please click the link below to send your complaint to a lawyer to evaluate your claim at no cost or obligation.
Last updated on Feb-19-08